Lv33
236 积分 2025-11-07 加入
[Guideline for HER2 testing in breast cancer (2024 version)]
7小时前
待确认
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1天前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
18天前
已完结
Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer
18天前
已完结
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
18天前
已完结
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
19天前
已完结
Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial
6个月前
已关闭
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
6个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
6个月前
已完结
Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
6个月前
已完结
皖公网安备34019202002308
